Related Experiment Video
Updated: Jul 1, 2025

Robotic D3 Partial Duodenal Resection with Primary Side-to-Side Anastomosis
Published on: December 15, 2023
Incidence and factors associated with stent dysfunction and pancreatitis after gastroduodenal stenting for malignant
Daiki Yamashige1, Susumu Hijioka1, Yoshikuni Nagashio1
1Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital Japan, Chuo-ku, Japan.
This study found that Niti-S stent deployment significantly reduced stent dysfunction in malignant gastric outlet obstruction (mGOO) patients. Main pancreatic duct caliber less than 3 mm independently predicted pancreatitis, guiding better stent selection for mGOO.
Area of Science:
- Gastroenterology
- Endoscopic procedures
- Oncology
Background:
- Endoscopic gastroduodenal stent (GDS) deployment is standard for malignant gastric outlet obstruction (mGOO).
- Stent dysfunction (SD) and pancreatitis are common complications.
- Investigating factors influencing SD and pancreatitis is crucial for optimizing patient outcomes.
Purpose of the Study:
- To determine the incidence of stent dysfunction (SD) and pancreatitis after GDS deployment for mGOO.
- To identify factors contributing to SD and pancreatitis.
- To evaluate the impact of stent type and patient factors on outcomes.
Main Methods:
- Retrospective review of 203 patients undergoing GDS for mGOO.
- Analysis of stent dysfunction (tumor ingrowth, kinking, migration) and pancreatitis incidence.
- Multivariate analysis to identify significant predictors of SD and pancreatitis.
Main Results:
- Stent dysfunction occurred in 33.5% of patients; cumulative incidence reached 41.1%.
- Niti-S stent deployment was associated with significantly reduced SD (sHR 0.26, P=0.01).
- Main pancreatic duct caliber < 3 mm independently predicted pancreatitis (OR 6.8, P=0.03).
Conclusions:
- Niti-S pyloric/duodenal stent deployment significantly lowers SD incidence in mGOO.
- Stent selection, patient life expectancy, and main pancreatic duct caliber are key considerations for GDS placement.
- Optimizing GDS strategy can improve outcomes for mGOO patients.
Related Concept Videos
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Acute Pancreatitis II: Clinical Manifestations and Management
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

